<DOC>
	<DOCNO>NCT00565591</DOCNO>
	<brief_summary>This open label single blind study determine safety albuterol sulfate dry powder novel inhaler observe potential occurrence reflex bronchial constriction inhalation increase dos compound .</brief_summary>
	<brief_title>Study Mild Intermittent Asthma Assess Topical Safety Tolerability Albuterol Sulfate Acu-30™ DPI</brief_title>
	<detailed_description>This single blind ( investigator unblinded ) , open label , single exposure , non-randomized , single center , outpatient , stepwise , rise dose study male subject mild intermittent asthma assess topical safety tolerability Albuterol Sulfate Acu-30™ DPI , compare Placebo Acu-30™ DPI . Increasing dos drug administer sequential fashion 4 step 3 different subject step ( total 12 subject ) mild intermittent asthma step .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Inclusion Criteria Mild intermittent asthma ( meet GINA specification www.ginasthma.com ) Medically normal subject significant abnormal finding No tobacco ( nicotine product ) use least 2 year study start Normal ( abnormal clinically insignificant ) laboratory value screen ( potassium glucose level ) No significant medical surgical condition ( COPD , cystic fibrosis , severe allergic rhinitis ) Past present history experience allergic reaction medications/formulations administer study , opinion Principal Investigator , suggest increase potential adverse hypersensitivity Subject abnormal screening visit vital sign clinical laboratory evaluation consider clinically significant Principal Investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>asthma</keyword>
	<keyword>inhaler device</keyword>
	<keyword>albuterol sulfate</keyword>
</DOC>